English
Arabic
Hebrew
USD / $
EUR / €
Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous
NEW
Facebook
Instagram
Youtube
Telegram
Search
Home
Products
Shop
About us
Contact us
Privacy Policy
Cart
Refunds
Account
Wishlist
All categories
A Digestion and Metabolism
B blood circulation
C cardiovascular system
Contrast agents
D skin preparations
E Hematopoietic organ drugs
F cranial brain system
G Urogenital system
H hormone preparations
J Anti-infectious drugs
K sex hormone
M Musculo-skeletal system
Medical excipients
medical instruments
N nervous system drugs
O Oncology adjuvant drugs
Oncology drugs
Breast glands and blood
digestion/transplantation
neurological / endocrine
reproductive / urinary
respiratory/skeleton system
skin / lymph
P anthelmintics
R Respiratory system
S sense organ
sexual health products
man
woman
V Antidote
W cold and fever reduction
X Infectious diseases
Search
Sign In
1
Compare
Wishlist
No products in the wishlist.
Return To Shop
0
Wishlist
Cart
No products in the cart.
Return To Shop
0
Cart
Home
Products
Shop
About us
Contact us
Privacy Policy
Cart
Refunds
Русский
الدول العربية
Home
Compare
Action
Delete
Image
Title
iptacopan Capsules Original drug Chinese packaging
Price
Button
阅读更多
Excerpt
On June 18, 2024, Ferheda® (iptacopan hydrochloride capsules) were gradually put on sale in China. Iptacopam is the world's first specific oral inhibitor of complement factor B, which acts on the proximal pathway of the immune system's complement bypass pathway, can fully control intravascular hemolysis and extravascular hemolysis, make up for the defects of anti-C5 antibody treatment, and is used to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not received complement inhibitor treatment before. Recently, Novartis' oral monotherapy, iptacopan hydrochloride capsules (iptacopan), was approved for marketing by the China National Medical Products Administration (NMPA) for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not received complement inhibitor treatment before. Public information shows that this is a "first-in-class" complement pathway factor B inhibitor and the first oral monotherapy approved by the US FDA for the treatment of adult PNH. It was listed by industry media Evaluate as one of the 10 potential blockbuster therapies worthy of attention. The approval of Iplocopam in China has also attracted people's attention to PNH. PNH is a chronic, progressive, debilitating, life-threatening disease that has been included in China's "First List of Rare Diseases". The disease often occurs in young and middle-aged people, accounting for about 77% of those aged 20 to 40. Studies have found that the 5-year mortality rate of PNH patients is as high as 35%, and the median survival period is about 10 years [1]. The arrival of Iplocopam provides a new type of targeted treatment option for PNH patients. In today's article, the WuXi AppTec content team will introduce the century-long history of mankind's efforts to tackle PNH disease based on public information.
Stock status
In stock
Select all
Add to cart
Remove
Apply
Compare more products
Home
Shop
Wishlist
Delivery
More
More
Home
Products
Shop
About us
Contact us
Privacy Policy
Cart
Refunds